Imiquimod 5% Cream Treatment for Actinic Keratosis

Licensed Dosing Regimen

The British Association of Dermatologists recommends applying imiquimod 5% cream at night, 3 times per week for 4 weeks, which can be repeated for an additional 4 weeks if needed, washing off after 8 hours 1, 2
The application frequency is 3 times per week, with a duration of 4-week course, repeatable for another 4 weeks if clearance is incomplete 1, 2, 3, 4
Apply at night and wash off with mild soap and water after 8 hours 1, 2

The treatment is only used for non-hyperkeratotic, non-hypertrophic actinic keratoses on the face or scalp in immunocompetent adults 1, 2, 3, 4
It is used when cryotherapy is limited by lesion size or number, or other topical options are contraindicated 1, 2, 3, 4

The British Association of Dermatologists guidelines demonstrate that the licensed regimen achieves comparable efficacy to longer protocols, with a strength of recommendation A and level of evidence 1++ 1, 2, 3, 4
Complete clearance rates are 48-57% with the 3 times weekly for 16 weeks regimen 1, 2, 3
Long-term durability shows that 76% of patients maintained clearance at 12 months, superior to 5-FU and cryosurgery 1, 2, 3, 5
Sustained benefit is seen in 75% of patients at 16 months with 3 times weekly for 8 weeks 1, 2, 4

Twice weekly for 16 weeks achieves 57% clearance but with lower long-term maintenance (57% vs 75% at 16 months) 1, 2, 5

The British Association of Dermatologists recommends warning patients extensively before starting treatment to prevent premature discontinuation 1, 2, 5
Expected local reactions include erythema, flaking, and scabbing, which occur in most patients and are signs the medication is working 1, 2
Severe reactions occur in 20.6-41.5% of patients, and treatment interruption may be necessary 6
Systemic symptoms, such as flu-like illness, occur in 3.7% of patients 6
Discontinuation rates are low, with only 0.6-1.2% discontinuing due to adverse events despite common reactions 6, 7

The American Academy of Dermatology recommends not applying imiquimod 5% cream to hyperkeratotic or hypertrophic lesions, as these require alternative treatments 1, 2, 3, 4